SYF684d08d230fa430cb2cb44a3ab955b1aRegistry ID: 2023-508069-34-01|RecruitingPhase 4
Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab
Amsterdam UMCCTIS (EMA)
Loading search results
interventional
N/A
1 country
1
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 23, 2024
Actual (reported)Identification of cell/molecular biomarkers correlated with individual patients’ responses. These could be: frequencies of cell (sub)populations, gene expression pattern, cell activation statues/phenotype, expression/production pattern of cell products
Identification of immunological mechanisms behind responses to mepolizumab
Evidence for the effectiveness in in vitro setting of mepolizumab in certain CRSsNP patients / endotypes
For CRSwNP group: Change in SNOT-22 from baseline to 6 months post-treatment
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Nucala 100 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Nucala 100 mg solution for injection in pre-filled pen
Named ingredient: mepolizumab
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Amsterdam UMC
Amsterdam, 1081 HV, Netherlands
Dr. Sietze Reitsma
First Submitted
February 23, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment
Contact the study team to confirm eligibility.